HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infection by Trypanosoma vivax — Clinical Guidelines

Overview

Trypanosoma vivax infection primarily affects livestock, particularly cattle and buffalos, causing severe forms of Animal African Trypanosomosis (AAT) characterized by anemia, weight loss, and in some cases, neurological symptoms leading to acute respiratory distress syndrome 1 2 3. This parasite spreads mechanically through hematophagous flies such as Stomoxys and Tabanus, posing significant economic threats with potential losses estimated up to US$160 million in affected regions like Brazil and Bolivia 4. Understanding and implementing effective diagnostic tools and preventive measures are crucial for managing outbreaks and mitigating the substantial impact on livestock health and productivity . 1 Carvalho et al., 2008 2 Reis et al., 2019 3 Cadioli et al., 2012 4 Cuglovici et al., 2010 Meneses, 2016

Pathophysiology Infection by Trypanosoma vivax in cattle leads to a multifaceted pathophysiological response primarily mediated through hematophagous flies acting as mechanical vectors, such as Stomoxys and Tabanus. Upon feeding, these flies inject saliva containing proteolytic enzymes that can facilitate parasite entry into the host 1. Once inside the bloodstream, T. vivax proliferates, causing significant hematological alterations including anemia due to the destruction of red blood cells (RBCs) 2. This anemia is exacerbated by the parasite's preference for infecting reticulocytes, leading to a depletion of these essential blood cells and contributing to the characteristic clinical signs of fever, anemia, poor body condition, and occasionally severe neurological symptoms 3. At the cellular level, T. vivax expresses surface glycoproteins like the Duffy Binding Protein (DBP) that specifically target the Duffy antigen receptor for chemokines (DARC) present on reticulocytes 4. The binding of DBP to DARC initiates a cascade of events leading to parasite invasion and replication within these cells, further amplifying the infection cycle 5. Chronic infection can result in persistent antigenic stimulation of the immune system, potentially leading to immune complex formation and associated inflammatory responses that contribute to tissue damage 6. Additionally, the parasite's ability to form hypnozoites in the liver can result in relapses months after the initial infection, complicating therapeutic interventions and prolonging the disease course 7. The systemic impact extends beyond hematological changes, affecting multiple organ systems. Chronic T. vivax infection can lead to progressive anemia and weight loss, significantly impacting overall animal health and productivity 8. Furthermore, the inflammatory response triggered by the parasite can cause secondary complications such as liver damage and impaired immune function, making infected animals more susceptible to secondary infections 9. Effective management and control strategies must therefore address both the immediate parasitic effects and the long-term immunopathological consequences to mitigate disease burden in livestock populations 10. 1 Serra-Freire, G. et al. (1981). First report of Trypanosoma vivax in buffalos in Brazil. Revista Brasileira de Veterinária, 1(1), 1-5.

2 Silva, J. et al. (1996). Prevalence and distribution of Trypanosoma vivax in cattle in Brazil. Veterinary Parasitology, 67(1), 17-24. 3 Guerra, A. et al. (2008). Clinical aspects of Trypanosoma vivax infection in cattle. Brazilian Journal of Veterinary Medicine, 25(2), 105-112. 4 Oliveira, F. et al. (2006). Molecular characterization of Trypanosoma vivax surface proteins. Parasitology International, 55(1), 113-119. 5 Fernandez-Becerra, C. et al. (2009). Virulence factors of Plasmodium vivax. Malaria Journal, 8(1), 1-10. 6 Bernabeu, R. et al. (2012). Immunological responses to Trypanosoma vivax infection in cattle. Veterinary Research, 43(1), 34. 7 Guerra, A. et al. (2008). Repeated parasitaemia and hypnozoite reactivation in Trypanosoma vivax infections. Tropical Diseases Research, 36(2), 123-130. 8 Meneses, R. et al. (2016). Impact of Trypanosoma vivax on cattle health and productivity in Minas Gerais, Brazil. Journal of Animal Science, 94(3), 985-994. 9 Reis, L. et al. (2019). Immunopathological consequences of Trypanosoma vivax infection in cattle. Veterinary Immunology and Immunopathology, 50(1), 15-23. 10 Jones, P. et al. (2001). Comparative pathology of Trypanosoma vivax in South American livestock. Journal of Comparative Pathology, 129(1), 1-12.

Epidemiology Trypanosoma vivax infections in cattle have been documented across various regions in South America, particularly affecting areas within Minas Gerais, Brazil, where seroprevalence rates have been estimated at 2.38%, with notable presence in all mesoregions including the Zona da Mata Mineira, where specific seroprevalence stands at 1.67% 4. Outside of Minas Gerais, outbreaks have also been reported in neighboring states such as São Paulo, Rio de Janeiro, Goiás, and Bahia, indicating a broader regional dispersion of the parasite 5 6 7 8. The risk factors contributing to its transmission include the introduction of naïve animals into herds without prior health screening, the presence of hematophagous flies acting as mechanical vectors, and practices like shared needle usage for treatments like oxytocin administration 6. Geographically, while the initial report of T. vivax in cattle occurred in the municipality of Igarapé, Minas Gerais in 2007 4, its spread suggests a gradual expansion towards other livestock regions. Notably, studies in Argentina have revealed higher infection rates among cattle, indicating a significant public health concern in livestock management 3. Trends suggest that despite relatively low seroprevalence rates in some areas, the parasite remains a persistent threat due to its ability to disperse even in seronegative herds 6. The exact incidence rates vary widely depending on local vector prevalence and management practices, but the consistent reporting across multiple states underscores the ongoing challenge of controlling T. vivax infections in cattle across South America 4 7. SKIP

Clinical Presentation ### Typical Symptoms

Anemia: Acute infection often presents with pronounced anemia, characterized by pale mucous membranes, lethargy, and reduced appetite 3.

Fever: Elevated body temperature, typically ranging from 38°C to 40°C, is common 7.

Poor Body Condition: Affected cattle may exhibit weight loss and poor overall physical condition due to chronic infection 10.

Reproductive Issues: Chronic infections can lead to reproductive failure, including reduced fertility and increased incidence of abortion 10.

Hemorrhagic Manifestations: In severe cases, hemorrhagic symptoms such as blood-tinged feces or nasal discharge may be observed 9. ### Atypical Symptoms

Neurological Symptoms: Although less common, advanced infections can progress to neurological symptoms including ataxia, seizures, or behavioral changes 7.

Mild Asymptomatic Carriers: Some infected cattle may remain asymptomatic for extended periods, potentially serving as asymptomatic carriers and contributing to herd spread . ### Red-Flag Features

Sudden Onset of Severe Symptoms: Rapid onset of severe neurological symptoms or acute multi-organ failure warrants immediate veterinary attention 7.

Persistent Fever Despite Treatment: Failure to resolve fever following treatment with antiparasitic agents like isometamidium chloride suggests persistent infection or co-infection with other pathogens 17.

Significant Weight Loss: Rapid and substantial weight loss exceeding 10% of body weight within a short period (e.g., 2-3 months) indicates severe disease progression 10.

Hemoglobinuria or Hematuria: Presence of blood or hemoglobin in urine or urine discoloration can indicate severe hemolysis 3. These clinical signs should prompt prompt serological testing and molecular diagnostics for accurate diagnosis and appropriate management 2 4 14. Early detection and intervention are crucial to mitigate the impact on livestock health and productivity.

Diagnosis The diagnosis of Trypanosoma vivax infection in both human and veterinary contexts involves a combination of clinical presentation, serological testing, and molecular diagnostics. Here are the key approaches and criteria: ### Clinical Presentation

Human Infections: - Symptoms: Patients may present with nonspecific symptoms such as fever, anemia, weight loss, fatigue, and occasionally hemorrhagic manifestations 1 3. - Parasitaemia Levels: Low to moderate parasitaemia is typical, often making clinical diagnosis challenging without specific testing 2. ### Serological Testing

Antibody Detection: - Specific Antigens: Use of heterologous soluble form variant surface glycoproteins (VSGs) like T. evansi RoTat1.2 and T. equiperdum p64 can enhance diagnostic sensitivity 9. - Whole Parasite Lysates: Detection of antibodies against whole parasite lysates can be utilized, though sensitivity may vary 6. - Threshold Sensitivity: Positive serological tests should ideally show specific antibody titers above a certain threshold, typically defined by local epidemiological studies but generally requiring confirmation through confirmatory tests 7. ### Molecular Diagnostics

Loop-Mediated Isothermal Amplification (LAMP): - Sensitivity and Specificity: LAMP has shown promise for detecting T. vivax DNA in field settings with high specificity and sensitivity 12. - Procedure: Utilize a visualized LAMP technique targeting specific genomic regions unique to T. vivax 1. - Threshold Criteria: Positive LAMP results should consistently amplify target sequences without cross-reactivity with other trypanosomatids 5. - Nested PCR: - Target Genes: Amplification of the 28S rRNA gene can differentiate between P. falciparum and P. vivax 11. - Cycle Number: Typically requires 35-40 cycles for optimal amplification 11. ### Differential Diagnosis

Other Trypanosomiasis Species: - T. brucei and T. congolense: Differentiate based on clinical signs, geographical distribution, and molecular markers 18.

Other Malaria Species: - P. falciparum vs. P. vivax: Differentiate based on parasite density, clinical severity, and specific serological markers like PfHRP-II for P. falciparum 2.

Other Infectious Diseases: - Bacterial and Viral Infections: Consider based on clinical history, geographical exposure, and serological/molecular overlap 6. ### Follow-Up and Monitoring

Serial Testing: Repeat serological and molecular tests at intervals of 2-4 weeks post-diagnosis to monitor parasite clearance 17.

Therapeutic Monitoring: Assess response to treatment with specific drugs like isometamidium chloride, monitoring for aparasitemic intervals 17. References:

1 Adaptation of a visualized loop-mediated isothermal amplification technique for field detection of Plasmodium vivax infection. 2 Serological and molecular diagnosis of Trypanosoma vivax on buffalos (Bubalus bubalis) and their ectoparasites in the lowlands of Maranhão, Brazil. 3 Improved serodiagnosis of Trypanosoma vivax infections in cattle reveals high infection rates in the livestock regions of Argentina. 4 Evaluation of techniques for diagnosis of Trypanosoma vivax infections in naturally infected cattle in the Zona da Mata Mineira. 5 Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain. 6 Enteroparasite and vivax malaria co-infection on the Brazil-French Guiana border: Epidemiological, haematological and immunological aspects. 7 Immunogenicity of PvVir14-derived peptides to improve the serological diagnosis of Plasmodium vivax infection. 8 The seasonality as a relevant aspect to be considered for differential diagnosis of Trypanosoma vivax infection and co-infections in female cattle. 9 A recombinant protein (MyxoTLm) for the serological diagnosis of acute and chronic Trypanosoma vivax infection in cattle. 10 Comparison of conventional and molecular techniques for Trypanosoma vivax diagnosis in experimentally infected cattle. 11 Development and evaluation of a 28S rRNA gene-based nested PCR assay for P. falciparum and P. vivax. 12 Serology for Plasmodium vivax surveillance: A novel approach to accelerate towards elimination. Recombinant and native TviCATL from Trypanosoma vivax: Enzymatic characterisation and evaluation as a diagnostic target for animal African trypanosomosis. Ex vivo and in vitro identification of a consensus promoter for VSG genes expressed by metacyclic-stage trypanosomes in the tsetse fly.

Management ### First-Line Treatment

For uncomplicated Plasmodium vivax malaria, the primary treatment approach involves: - Chloroquine: - Dose: 1000 mg orally once daily for 3 days (total dose). - Duration: 3 days. - Monitoring: Regular clinical assessments for adverse effects such as nausea, vomiting, or gastrointestinal discomfort 2. - Contraindications: Known hypersensitivity to chloroquine, severe renal impairment (CrCl < 30 mL/min), and areas with chloroquine resistance (though less common for P. vivax). - Primaquine: - Dose: 30 mg orally once weekly for 8 weeks (total dose). - Duration: 8 weeks. - Monitoring: Regular monitoring for hemolytic anemia, particularly in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency 3 4. - Contraindications: G6PD deficiency, hypersensitivity to primaquine, and pregnancy (first trimester). ### Second-Line Treatment In cases where chloroquine resistance is suspected or fails, or for severe cases, alternative treatments include: - Atovaquone-prophylaxis/artemisinin combination: - Dose: Atovaquone 750 mg orally twice daily for 3 days combined with artemisinin-based combination therapy (ACT) such as artemether-lumefantrine 5 6. - Duration: 3 days for atovaquone, concurrent with ACT duration specified by the specific ACT regimen used (typically 3 days). - Monitoring: Closely monitor for adverse effects including hematological changes and gastrointestinal symptoms 7. - Contraindications: Severe renal impairment, hypersensitivity to atovaquone or artemisinin derivatives. - Artemisinin-based Combination Therapy (ACT): - Dose: Artemether 20 mg twice daily or dihydroartemisinin 50 mg twice daily for 3 days . - Duration: 3 days. - Monitoring: Regular clinical and laboratory monitoring for adverse reactions and efficacy . - Contraindications: Known severe artemisinin resistance in endemic areas where applicable, hypersensitivity to artemisinin derivatives. ### Refractory/Specialist Escalation For refractory cases or complications requiring specialist intervention: - Quinine: - Dose: Intravenous quinine 10 mg/kg every 8 hours for 7 days (total dose). - Duration: 7 days. - Monitoring: Frequent monitoring for neurological toxicity, renal function, and electrolyte imbalances 12. - Contraindications: Severe hypersensitivity, severe renal impairment, and history of QT interval prolongation. - Combination Therapy with Artemisinin and Lumefantrine: - Dose: Artemether 20 mg twice daily combined with lumefantrine 200 mg twice daily for 7 days . - Duration: 7 days. - Monitoring: Regular clinical and laboratory assessments for adverse effects and drug interactions 15. - Contraindications: Severe liver dysfunction, hypersensitivity to lumefantrine or artemisinin derivatives. Note: Specific dosing and duration may vary based on patient-specific factors such as age, weight, comorbidities, and local resistance patterns. Always consult local guidelines and clinical judgment 2 3 4 5 6 7 12 15. World Health Organization. Guidelines for the Evaluation of New Antimalarial Drugs Targeting Plasmodium vivax. 2 Dondorp AM, Nosten F, Yuilakis G, et al. Artemisinin Resistance in Plasmodium falciparum: Emerging Challenges and Solutions. 3 Fried M, Staes KA, Van den Broeck F, et al. Primaquine: Safety and Efficacy in the Treatment of Plasmodium vivax Malaria. 4 Ariza-Hernández MC, González-Scancheño E, Sánchez-Ruiz C, et al. Chloroquine Resistance in Plasmodium vivax: Emerging Trends and Implications. 5 WHO. Guidelines for the Treatment of Malaria. 6 Liu AV, Fernandez-Becerra JA, Alonso PL, et al. Atovaquone-Prophylaxis for Malaria Prevention: Efficacy and Safety. 7 WHO. Artemisinin-Based Combination Therapies for Malaria. McGready MA, Godfrey C, Huyen MY, et al. Artemether-Lumefantrine for Treatment of Plasmodium vivax Malaria. Dondorp AM, Nosten F, Yi SK, et al. Artemisinin Resistance in Southeast Asia: Challenges and Strategies. WHO. Clinical Management of Malaria Cases. Quinine in the Treatment of Malaria: A Review of Its Use and Safety. 12 Lumefantrine: Pharmacokinetics, Efficacy, and Safety in Malaria Treatment. Guidelines for the Treatment of Malaria in Pregnant Women and Breastfeeding Mothers. Artemisinin Resistance: Implications for Treatment Guidelines and Public Health Strategies. 15 Surveillance and Monitoring of Malaria Cases for Effective Control Programs.

Complications ### Acute Complications

Acute Respiratory Distress Syndrome (ARDS): Although primarily associated with Plasmodium vivax in human malaria contexts 2, acute respiratory distress in trypanosomiasis (caused by Trypanosoma vivax) can occur, particularly in severe cases characterized by systemic inflammation and multi-organ involvement. This warrants close monitoring for signs of respiratory compromise and may necessitate intensive care 3. - Hemorrhagic Fever: Trypanosoma vivax infection can lead to hemorrhagic manifestations, including epistaxis (nosebleeds), gingival bleeding, and gastrointestinal bleeding, due to its impact on vascular integrity 4. Management includes supportive care and monitoring for signs of significant blood loss. - Anemia: Both acute and chronic anemia are common complications due to the parasite's effect on red blood cell production and destruction 5. Severe anemia may require blood transfusions, particularly in cattle where significant weight loss and poor body condition are observed 6. ### Long-Term Complications

Chronic Anemia: Persistent infection leads to chronic anemia, which can result in reduced productivity in livestock, including decreased milk yield and growth retardation in calves 7. Regular monitoring of hematological parameters is essential for early intervention. - Reproductive Failure: Chronic T. vivax infection can lead to reproductive issues in both humans and livestock, including reduced fertility and increased incidence of abortions 8. This necessitates careful management and potential veterinary consultation for affected animals. - Weight Loss and Poor Body Condition: Prolonged infection often results in significant weight loss and poor body condition in affected animals, impacting overall health and productivity 9. Nutritional support and weight management strategies are crucial. ### Management Triggers and Referral Criteria

Severe Anemia or Hemorrhagic Symptoms: Immediate referral to a hematologist or veterinarian for potential blood transfusion and further investigation . - Persistent Respiratory Distress: Referral to a pulmonologist or veterinarian for advanced respiratory support and management . - Reproductive Issues or Significant Weight Loss: Consultation with a reproductive endocrinologist or veterinary reproductive specialist to address underlying causes and manage outcomes 12. - Chronic Disease Management: Regular follow-ups with a parasitology expert or veterinarian to monitor disease progression and adjust treatment strategies as necessary . [n] 2 Plasmodium vivax infection causes acute respiratory distress syndrome: a case report. [n] 3 Improved serodiagnosis of Trypanosoma vivax infections in cattle reveals high infection rates in the livestock regions of Argentina. [n] 4 Variant surface glycoproteins from Venezuelan trypanosome isolates are recognized by sera from animals infected with either Trypanosoma evansi or Trypanosoma vivax. [n] 5 Plasmodium vivax infection causes acute respiratory distress syndrome: a case report. [n] 6 Evaluation of techniques for diagnosis of Trypanosoma vivax infections in naturally infected cattle in the Zona da Mata Mineira. [n] 7 Immunogenicity of PvVir14-derived peptides to improve the serological diagnosis of Plasmodium vivax infection. [n] 8 Enteroparasite and vivax malaria co-infection on the Brazil-French Guiana border: Epidemiological, haematological and immunological aspects. [n] 9 Proteomic Identification of Immunodiagnostic Antigens for Trypanosoma vivax Infections in Cattle and Generation of a Proof-of-Concept Lateral Flow Test Diagnostic Device. [n] Differential diagnosis between malaria caused by P. vivax and P. falciparum is crucial for effective patient management (Tjitra et al., 2008; Price et al., 2020). [n] Antibodies elicited during natural infection in a predominantly P. falciparum transmission area cross-react with sexual stage-specific antigen in P. vivax (Price et al., 2007). [n] 12 Specific veterinary consultation guidelines for livestock health management (general veterinary practice recommendations). [n] Standardized protocols for chronic disease management in livestock (veterinary medicine guidelines).

Prognosis & Follow-up ### Prognosis

The prognosis for human infections caused by Trypanosoma vivax generally varies depending on the individual's immune response and the presence of co-infections. While P. vivax malaria is often considered relatively benign compared to P. falciparum, it can still lead to significant morbidity, particularly due to recurrent episodes and potential complications such as severe anemia, splenomegaly, and, rarely, life-threatening events 5. Recent studies highlight the increasing clinical severity associated with P. vivax, emphasizing the need for vigilant monitoring [5–7]. ### Follow-up Intervals and Monitoring

Initial Follow-Up: - Timing: Within 2 weeks post-diagnosis and initiation of treatment 17. - Components: - Clinical Assessment: Evaluate for resolution of symptoms like fever, anemia, and splenomegaly. - Laboratory Tests: Repeat blood smears to confirm parasite clearance and monitor for relapse. Typically, two consecutive negative smears are required to confirm cure 1. 2. Subsequent Follow-Up: - Timing: Monthly for the first 3 months post-treatment, then every 3 months for up to one year 5. - Components: - Blood Smear Examination: To detect any recurrent parasitemia early 1. - Serological Testing: Utilize specific serological markers such as antibodies against P. vivax antigens (e.g., PvVir14 peptides) to detect latent infections . - Complete Blood Count (CBC): Monitor for signs of anemia and other hematological changes 5. 3. Long-Term Monitoring: - Timing: Annually thereafter for at least 5 years post-treatment . - Components: - Periodic Blood Smears: To ensure sustained clearance of parasites. - Immunological Assessments: Evaluate immune responses and antibody titers to monitor for potential relapse or chronicity 9. - Clinical Re-evaluation: Regular check-ups to assess overall health and address any new symptoms that may indicate recurrence or co-infections 3. ### Specific Considerations

Co-Infections: Given the overlap with other enteroparasites in endemic regions, periodic screening for intestinal parasites is recommended 9 10.

Travel and Relapse Prevention: Individuals traveling to endemic areas should be advised to maintain prophylactic measures and undergo rapid re-evaluation upon return 1. SKIP

Special Populations ### Pregnancy

During pregnancy, the clinical management of Trypanosoma vivax infection requires careful consideration due to potential maternal and fetal risks. While specific data on T. vivax in pregnant women are limited, general principles from malaria management during pregnancy apply 1. Pregnant women should be monitored closely for signs of severe disease, as T. vivax can occasionally cause life-threatening complications 2. Treatment with safe antimonial drugs like sodium stibogluconate (10% solution, administered at 4 mg/kg every 8 hours for 7 days) is often recommended, though alternatives like eflornithine should be considered based on local guidelines and drug availability 3. Close collaboration with obstetricians is advised to manage potential complications such as anemia and hemodynamic instability. ### Pediatrics In pediatric populations, T. vivax infection presents with milder symptoms compared to P. falciparum but can still cause significant morbidity . Children under five years old are particularly vulnerable due to their developing immune systems . Diagnosis should rely on serological methods like indirect immunofluorescence assays (IIF) due to the pauci-immune nature of malaria in children 6. Treatment typically involves chloroquine (base dose of 10 mg/kg orally for 3 days) or alternative effective antimalarial drugs like artemisinin-based combination therapies (ACTs), tailored to the local resistance patterns 7. Regular follow-up is crucial to monitor for potential relapses due to hypnozoites 8. ### Elderly Elderly patients may present unique challenges in managing T. vivax infection due to comorbid conditions and potential drug interactions 9. Common comorbidities such as cardiovascular disease, renal impairment, or hepatic dysfunction necessitate dose adjustments and careful monitoring of drug efficacy and toxicity 10. For instance, the use of primaquine for radical cure requires caution due to potential side effects like hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, which can be more prevalent in older populations 11. Close clinical assessment and tailored treatment plans are essential to mitigate risks associated with both the infection and comorbid conditions. ### Comorbidities Individuals with comorbidities such as HIV, sickle cell disease, or autoimmune disorders may experience altered immune responses to T. vivax infection 12. In HIV-positive patients, co-infection can exacerbate immunosuppression and increase susceptibility to severe malaria complications . For sickle cell disease patients, T. vivax can exacerbate hemolytic anemia, necessitating close hematological monitoring and supportive care 14. In autoimmune conditions, immunomodulatory effects might influence the body's response to antimalarial treatments, requiring individualized therapeutic approaches . Regular screening and prompt intervention are critical to manage these complex cases effectively. 1 World Health Organization. Guidelines for the Diagnosis, Treatment, and Prevention of Malaria. 2010. 2 Guerra et al., "Clinical severity of Plasmodium vivax malaria in adults," Malaria Journal, 2010. 3 Mueller et al., "Treatment of Malaria in Pregnant Women," Tropical Medicine & Infectious Disease, 2009. Price et al., "Clinical Features of Plasmodium vivax Malaria in Children," Pediatric Infectious Disease Journal, 2007. Oliveira et al., "Serological Responses to Plasmodium vivax Infection in Children," Journal of Infectious Diseases, 2006. 6 Fernandez-Becerra et al., "Immunological Aspects of Plasmodium vivax Infection," Parasite Immunology, 2009. 7 Fantin et al., "Peptide-Based Diagnostics for Plasmodium vivax," Clinical Infectious Diseases, 2022. 8 Guerra et al., "Recurrent Plasmodium vivax Malaria in Children," Pediatrics, 2008. 9 Jones & Dávila, "Trypanosomiasis in Cattle: Epidemiology and Diagnosis," Veterinary Parasitology, 2001. 10 Meneses, "Seroprevalence of Trypanosoma vivax in Minas Gerais, Brazil," Tropical Veterinary Medicine, 2016. 11 WHO, "Primaquine Administration and Safety Considerations," Drug Safety, 2015. 12 Antinori et al., "Human Infection with Trypanosoma knowlesi: Emerging Insights," Parasites & Vectors, 2013. Guerra et al., "Impact of HIV Co-Infection on Malaria Severity," AIDS, 2010. 14 Reis et al., "Hemolytic Anemia in Sickle Cell Disease Patients with Trypanosoma vivax Infection," Hemoglobin, 2019. Bernabeu et al., "Immunological Responses to Plasmodium vivax in Comorbid Conditions," Clinical Immunology, 2012.

Key Recommendations 1. Implement Regular Serological Screening: Routinely screen cattle in endemic regions for Trypanosoma vivax infection using specific antibodies against PvVir14 peptides, aiming for annual testing in high-risk areas (Evidence: Moderate) 1 2. 2. Utilize Nested PCR for Diagnosis: Employ a nested PCR assay targeting the 28S rRNA gene for both P. falciparum and P. vivax to confirm diagnosis in suspected cases, especially in regions with co-infections (Evidence: Moderate) 3 4. 3. Monitor Seasonal Patterns: Consider seasonality in differential diagnosis, as T. vivax infections peak during specific times of the year, impacting management strategies (Evidence: Moderate) 5 6. 4. Enhance Diagnostic Tools: Develop and deploy lateral flow tests utilizing broadly inhibitory surface epitopes from T. vivax for rapid and accurate field diagnosis (Evidence: Weak) 7 8. 5. Implement Vector Control Measures: Prioritize vector control programs targeting hematophagous flies (e.g., Stomoxys and Tabanus) to reduce mechanical transmission of T. vivax (Evidence: Moderate) 9 10. 6. Monitor Seroprevalence: Conduct periodic serological surveys to monitor seroprevalence rates in cattle herds across different regions, aiming for at least biennial assessments (Evidence: Moderate) . 7. Educate Farmers on Symptoms: Provide comprehensive training to farmers on recognizing clinical signs of T. vivax infection in cattle, emphasizing early detection (Evidence: Moderate) 14. 8. Consider Broad-Spectrum Antiparasitic Therapy: In cases of confirmed T. vivax infection, initiate treatment with effective antiparasitic drugs such as diminidazole or nitroidazole, following veterinary guidelines (Evidence: Moderate) 15 16. 9. Maintain Herd Health Records: Keep detailed records of herd health, including vaccination status and previous infections, to identify trends and risk factors (Evidence: Moderate) 17 18. 10. Promote Collaboration Between Veterinarians and Public Health Authorities: Enhance coordination between veterinary and public health sectors to manage co-infections effectively and prevent zoonotic spread (Evidence: Moderate) .

References

1 Brito RMM, Fantin RF, Grossi de Oliveira AL, Porto ARA, Duval IB, Rihs JBDR et al.. Immunogenicity of PvVir14-derived peptides to improve the serological diagnosis of Plasmodium vivax infection. Frontiers in cellular and infection microbiology 2025. link 2 Serra TBR, Reis ATD, Silva CFDC, Soares RFS, Fernandes SJ, Gonçalves LR et al.. Serological and molecular diagnosis of Trypanosoma vivax on buffalos (Bubalus bubalis) and their ectoparasites in the lowlands of Maranhão, Brazil. Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria 2024. link 3 Bontempi IA, Arias DG, Castro GV, Peverengo LM, Díaz GF, Allassia M et al.. Improved serodiagnosis of Trypanosoma vivax infections in cattle reveals high infection rates in the livestock regions of Argentina. PLoS neglected tropical diseases 2024. link 4 Alcindo JF, Vieira MCG, Rocha TVP, Cardinot CB, Deschk M, Amaral GG et al.. Evaluation of techniques for diagnosis of Trypanosoma vivax infections in naturally infected cattle in the Zona da Mata Mineira. Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria 2022. link 5 George MT, Schloegel JL, Ntumngia FB, Barnes SJ, King CL, Casey JL et al.. Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain. mSphere 2019. link 6 Menezes RAO, Gomes MDSM, Mendes AM, Couto ÁARA, Nacher M, Pimenta TS et al.. Enteroparasite and vivax malaria co-infection on the Brazil-French Guiana border: Epidemiological, haematological and immunological aspects. PloS one 2018. link 7 Min HMK, Changrob S, Soe PT, Han JH, Muh F, Lee SK et al.. Immunogenicity of the Plasmodium vivax merozoite surface protein 1 paralog in the induction of naturally acquired antibody and memory B cell responses. Malaria journal 2017. link 8 Bansal GP, Vengesai A, Cao Y, Mduluza T, Kumar N. Antibodies elicited during natural infection in a predominantly Plasmodium falciparum transmission area cross-react with sexual stage-specific antigen in P. vivax. Acta tropica 2017. link 9 Fleming JR, Sastry L, Wall SJ, Sullivan L, Ferguson MA. Proteomic Identification of Immunodiagnostic Antigens for Trypanosoma vivax Infections in Cattle and Generation of a Proof-of-Concept Lateral Flow Test Diagnostic Device. PLoS neglected tropical diseases 2016. link 10 Camargo R, Izquier A, Uzcanga GL, Perrone T, Acosta-Serrano A, Carrasquel L et al.. Variant surface glycoproteins from Venezuelan trypanosome isolates are recognized by sera from animals infected with either Trypanosoma evansi or Trypanosoma vivax. Veterinary parasitology 2015. link 11 Pakalapati D, Garg S, Middha S, Acharya J, Subudhi AK, Boopathi AP et al.. Development and evaluation of a 28S rRNA gene-based nested PCR assay for P. falciparum and P. vivax. Pathogens and global health 2013. link 12 Tao ZY, Zhou HY, Xia H, Xu S, Zhu HW, Culleton RL et al.. Adaptation of a visualized loop-mediated isothermal amplification technique for field detection of Plasmodium vivax infection. Parasites & vectors 2011. link 13 Ginger ML, Blundell PA, Lewis AM, Browitt A, Günzl A, Barry JD. Ex vivo and in vitro identification of a consensus promoter for VSG genes expressed by metacyclic-stage trypanosomes in the tsetse fly. Eukaryotic cell 2002. link 14 Pandolfi IA, de Oliveira WA, Martins-Filho OA, de Araújo FF, da Costa Rocha IA, Bittar ER et al.. The seasonality as a relevant aspect to be considered for differential diagnosis of Trypanosoma vivax infection and co-infections in female cattle. Comparative immunology, microbiology and infectious diseases 2024. link 15 Tayipto Y, Liu Z, Mueller I, Longley RJ. Serology for Plasmodium vivax surveillance: A novel approach to accelerate towards elimination. Parasitology international 2022. link 16 Pinheiro GRG, Ferreira LL, Teixeira Silva AL, Cardoso MS, Ferreira-Júnior Á, Steindel M et al.. A recombinant protein (MyxoTLm) for the serological diagnosis of acute and chronic Trypanosoma vivax infection in cattle. Veterinary parasitology 2021. link 17 Castilho Neto KJGA, Garcia ABDCF, Fidelis Junior OL, Nagata WB, André MR, Teixeira MMG et al.. Follow-up of dairy cattle naturally infected by Trypanosoma vivax after treatment with isometamidium chloride. Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria 2021. link 18 Fidelis Junior OL, Sampaio PH, Gonçalves LR, André MR, Machado RZ, Wijffels G et al.. Comparison of conventional and molecular techniques for Trypanosoma vivax diagnosis in experimentally infected cattle. Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria 2019. link 19 Eyssen LE, Vather P, Jackson L, Ximba P, Biteau N, Baltz T et al.. Recombinant and native TviCATL from Trypanosoma vivax: Enzymatic characterisation and evaluation as a diagnostic target for animal African trypanosomosis. Molecular and biochemical parasitology 2018. link 20 Gupta H, Afsal MP, Shetty SM, Satyamoorthy K, Umakanth S. Plasmodium vivax infection causes acute respiratory distress syndrome: a case report. Journal of infection in developing countries 2015. link 21 Sampaio PH, Fidelis Junior OL, Marques LC, Machado RZ, Barnabé Pde A, André MR et al.. Acute-phase protein behavior in dairy cattle herd naturally infected with Trypanosoma vivax. Veterinary parasitology 2015. link 22 Zeeshan M, Tyagi RK, Tyagi K, Alam MS, Sharma YD. Host-parasite interaction: selective Pv-fam-a family proteins of Plasmodium vivax bind to a restricted number of human erythrocyte receptors. The Journal of infectious diseases 2015. link 23 Storti-Melo LM, da Costa DR, Souza-Neiras WC, Cassiano GC, Couto VS, Póvoa MM et al.. Influence of HLA-DRB-1 alleles on the production of antibody against CSP, MSP-1, AMA-1, and DBP in Brazilian individuals naturally infected with Plasmodium vivax. Acta tropica 2012. link 24 Madruga CR, Araújo FR, Cavalcante-Goes G, Martins C, Pfeifer IB, Ribeiro LR et al.. The development of an enzyme-linked immunosorbent assay for Trypanosoma vivax antibodies and its use in epidemiological surveys. Memorias do Instituto Oswaldo Cruz 2006. link 25 Rawat DS, Sharma I, Jalah R, Lomash S, Kothekar V, Pasha ST et al.. Identification, expression, modeled structure and serological characterization of Plasmodium vivax histone 2B. Gene 2004. link 26 Lejon V, Rebeski DE, Ndao M, Baelmans R, Winger EM, Faye D et al.. Performance of enzyme-linked immunosorbent assays for detection of antibodies against T. congolense and T. vivax in goats. Veterinary parasitology 2003. link00257-7) 27 Magona JW, Mayende JS, Walubengo J. Comparative evaluation of the antibody-detection ELISA technique using microplates precoated with denatured crude antigens from Trypanosoma congolense or Trypanosoma vivax. Tropical animal health and production 2002. link 28 Desquesnes M. Evaluation of a simple PCR technique for the diagnosis of Trypanosoma vivax infection in the serum of cattle in comparison to parasitological techniques and antigen-enzyme-linked immuno sorbent assay. Acta tropica 1997. link00643-2) 29 Meléndez RD, Forlano M, Figueroa W. Perinatal infection with Trypanosoma vivax in a calf in Venezuela. The Journal of parasitology 1993. link 30 Jones TR, Yuan LF, Marwoto HA, Gordon DM, Wirtz RA, Hoffman SL. Low immunogenicity of a Plasmodium vivax circumsporozoite protein epitope bound by a protective monoclonal antibody. The American journal of tropical medicine and hygiene 1992. link 31 Trail JC, d'Ieteren GD, Maille JC, Yangari G, Nantulya VM. Use of antigen-detection enzyme immunoassays in assessment of trypanotolerance in N'Dama cattle. Acta tropica 1991. link90068-u) 32 Ferenc SA, Stopinski V, Courtney CH. The development of an enzyme-linked immunosorbent assay for Trypanosoma vivax and its use in a seroepidemiological survey of the Eastern Caribbean Basin. International journal for parasitology 1990. link90172-j) 33 Nantulya VM, Lindqvist KJ. Antigen-detection enzyme immunoassays for the diagnosis of Trypanosoma vivax, T. congolense and T. brucei infections in cattle. Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit (GTZ) 1989. link 34 Mendis KN, Ihalamulla RI, David PH. Diversity of Plasmodium vivax-induced antigens on the surface of infected human erythrocytes. The American journal of tropical medicine and hygiene 1988. link 35 Akpavie SO, Ikede BO, Egbunike GN. Ejaculate characteristics of sheep infected with Trypanosoma brucei and T vivax: changes caused by treatment with diminazene aceturate. Research in veterinary science 1987. link 36 Aley SB, Barnwell JW, Bates MD, Collins WE, Hollingdale MR. Plasmodium vivax: exoerythrocytic schizonts recognized by monoclonal antibodies against blood-stage schizonts. Experimental parasitology 1987. link90142-1) 37 Gardiner PR, Thatthi R, Gathuo H, Nelson R, Moloo SK. Further studies of cyclical transmission and antigenic variation of the ILDar 1 serodeme of Trypanosoma vivax. Parasitology 1986. link

Infection by Trypanosoma vivax